Expression of human immunodeficiency virus type 1 gp120 from herpes simplex virus type 1-derived amplicons results in potent, specific, and durable cellular and humoral immune responses

Journal of Virology

Volumn 76, Issue 11, 2002, Pages 5565-5580

  Hocknell, Peter K ^a   Wiley, Rebecca D ^a   Wang, Xiuqing ^a   Evans, Thomas G ^a   Bowers, William J ^a   Hanke, Tomas ^a   Federoff, Howard J ^a   Dewhurst, Stephen ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN GP 120; IMMUNOGLOBULIN G; VIRUS VECTOR;

AMPLICON; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CELLULAR IMMUNITY; CONCENTRATION RESPONSE; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DRUG DELIVERY SYSTEM; FEMALE; HERPES SIMPLEX VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMORAL IMMUNITY; IMMUNE RESPONSE; MOUSE; NONHUMAN; PLASMID; PRIORITY JOURNAL; T LYMPHOCYTE; VIRUS PARTICLE;

ANIMALS; ANTIBODY FORMATION; CELL LINE; DEFECTIVE VIRUSES; DNA, VIRAL; FEMALE; GENE EXPRESSION; GENETIC VECTORS; HELPER VIRUSES; HERPESVIRUS 1, HUMAN; HIV ENVELOPE PROTEIN GP120; HUMANS; IMMUNITY, CELLULAR; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; VIRION;

EID: 0036094421     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.76.11.5565-5580.2002     Document Type: Article

References (59)

1. Varicella-zoster virus infection of human dendritic cells and transmission to T cells: Implications for virus dissemination in the host
2. d: Expression, refolding and crystallization
3. The crystal structure of H-2Dd MHC class I complexed with the HIV-1-derived peptide P18-I10 at 2.4 Å resolution: Implications for T-cell and NK cell recognition
4. Increased immune response elicited by DNA vaccination with a synthetic gp120 sequence with optimized codon usage
5. Varicella vaccine: Genesis, efficacy, and attenuation
6. Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination
7. + cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection
8. Antiviral pressure exerted by HIV-1-specific cytotoxic T lymphocytes (CTLs) during primary infection demonstrated by rapid selection of CTL escape virus
9. Expression of vhs and VP16 during HSV-1 helper virus-free amplicon packaging enhances titers
10. Discordance between expression and genome transfer titering of HSV amplicon vectors: Recommendation for standardized enumeration
11. Effect of prior exposure to herpes simplex virus 1 on viral vector-mediated tumor therapy in immunocompetent mice
12. Helper virus-free transfer of herpes simplex virus type 1 plasmid vectors into neural cells
13. A defective HSV-1 vector expresses Escherichia coli β-galactosidase in cultured peripheral neurons
14. Immunogenicities of intravenous and intramuscular administrations of modified vaccinia virus Ankara-based multi-CTL epitope vaccine for human immunodeficiency virus type 1 in mice
15. Immunization with recombinant varicella-zoster virus expressing herpes simplex virus type 2 glycoprotein D reduces the severity of genital herpes in guinea pigs
16. Pre-existing herpes simplex virus 1 (HSV-1) immunity decreases, but does not abolish, gene transfer to experimental brain tumors by a HSV-1 vector
17. Herpes simplex virus turns off the TAP to evade host immunity
18. Herpes simplex virus with highly reduced gD levels can efficiently enter and spread between human keratinocytes
19. + T-cell depletion in simian immunodeficiency virus-infected macaques
20. Psychosocial influences on immune responses to HSV-1 infection in BALB/c mice
21. Genetically engineered vaccines for control of Aujeszky's disease (pseudorabies)
22. Reinfections and site-specific immunity in herpes simplex virus infections
23. Mature dendritic cells infected with herpes simplex virus type 1 exhibit inhibited T-cell stimulatory capacity
24. Oka/Merck varicella vaccine in healthy children: Final report of a 2-year efficacy study and 7-year follow-up studies
25. d complexed with an immunodominant peptide from human immunodeficiency virus envelope glycoprotein 120
26. A novel approach for herpes simplex virus type 1 amplicon vector production, using the Cre-loxP recombination system to remove helper virus
27. Herpes simplex virus type 1 amplicon vectors with glucocorticoid-inducible gene expression
28. The JAM test. A simple assay for DNA fragmentation and cell death
29. Immature monocyte-derived dendritic cells are productively infected with herpes simplex virus type 1
30. Mechanisms of immunization with a replication-defective mutant of herpes simplex virus 1
31. Vaccine protection against simian immunodeficiency virus by recombinant strains of herpes simplex virus
32. Analysis of the mechanism for extracellular processing in the presentation of human immunodeficiency virus-1 envelope protein-derived peptide to epitope-specific cytotoxic T lymphocytes
33. Development of a FLP/frt system for generating helper-dependent adenoviral vectors
34. Quantitation of HIV-1-specific cytotoxic T lymphocytes and plasma load of viral RNA
35. A helper-dependent adenovirus vector system: Removal of helper virus by Cre-mediated excision of the viral packaging signal
36. A T-cell receptor V alpha domain expressed in bacteria: Does it dimerize in solution?
37. Effect of Towne live virus vaccine on cytomegalovirus disease after renal transplant. A controlled trial
38. Improved helper virus-free packaging system for HSV amplicon vectors using an ICP27-deleted, oversized HSV-1 DNA in a bacterial artificial chromosome
39. Inhibition of dendritic cell maturation by herpes simplex virus
40. Optimization of the helper-dependent adenovirus system for production and potency in vivo
41. + lymphocytes
42. Expression of hepatitis B virus S gene by herpes simplex virus type 1 vectors carrying alpha- and beta-regulated gene chimeras
43. Degenerate MHC restriction reveals the contribution of class I MHC molecules in determining the fine specificity of CTL recognition of an immunodominant determinant of HIV-1 gp160 V3 loop
44. Construction of Oka varicella vaccine expressing human immunodeficiency virus env antigen
45. The herpes simplex virus amplicon: A new eucaryotic defective-virus cloning-amplifying vector
46. Herpes simplex virus type 1 pathogenicity in footpad and ear skin of mice depends on Langerhans cell density, mouse genetics, and virus strain
47. Langerhans cell density and activity in mouse skin and lymph nodes affect herpes simplex type 1 (HSV-1) pathogenicity
48. Role of Langerhans cells and Thy. 1+ effector cells in herpes simplex virus-1 infection in the skin of newborn mice
49. Skin Langerhans cells play an essential role in the defense against HSV-1 infection
50. T-cell death and memory
51. The status of cytomegalovirus vaccine
52. An enhanced packaging system for helper-dependent herpes simplex virus vectors
53. Generation of monoclonal antibodies against the amino terminus of gp120 that elicit antibody-dependent cellular cytotoxicity
54. Efficient FLPe recombinase enables scalable production of helper-dependent adenoviral vectors with negligible helper-virus contamination
55. Bovine herpesvirus-1 vaccines
56. Live attenuated pseudorables virus expressing envelope glycoprotein E1 of hog cholera virus protects swine against both pseudorabies and hog cholera
57. Dendritic cells transduced with hsv-1 amplicons expressing prostate-specific antigen generate antitumor immunity in mice
58. + T lymphocytes